Usefulness of neuron-specific enolase as a serum marker of metastatic melanoma.
biomarker
lactate dehydrogenase
malignant melanoma
mucosal melanoma
neuron-specific enolase
Journal
The Journal of dermatology
ISSN: 1346-8138
Titre abrégé: J Dermatol
Pays: England
ID NLM: 7600545
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
14
04
2020
accepted:
13
06
2020
pubmed:
1
8
2020
medline:
15
5
2021
entrez:
1
8
2020
Statut:
ppublish
Résumé
Treatment strategies for advanced melanoma are dramatically changing, due to immune-checkpoint inhibitors and BRAF/MEK inhibitors. Nevertheless, reliable serum markers for evaluation of treatment responses and the outcome are still limited. Some previous reports suggested that serum neuron-specific enolase (sNSE) may be a useful marker for melanoma; however, its usefulness is controversial. Moreover, NSE has not been examined in vitro by using melanoma cell lines. We retrospectively evaluated sNSE and serum lactate dehydrogenase (sLDH) levels at the initial diagnosis and during therapy in 33 melanoma patients of various stages. We analyzed the NSE concentrations in cell lysates and supernatants from melanoma cell lines by enzyme-linked immunosorbent assay. The median sNSE was significantly higher in stage IV patients compared with stages I/II and III (16.3, 12.7 and 12.1 ng/mL, respectively). sNSE was elevated in 20% (2/10) of stage III and 61.1% (11/18) of stage IV patients but not in stages I/II. sNSE and sLDH tended to correspond to the total tumor volume (P = 0.48 and 0.58; 95% confidence intervals, 0.005-0172 and 0.776-0.836, respectively). The coincidence rate of sNSE and sLDH in stage IV at the initial diagnosis was 11 of 18 (61.1%). Of the remaining patients, elevated sNSE but not sLDH was observed in five patients (27.8%) and elevated sLDH but not sNSE was observed in two (11.1%). Four of the five patients showing elevated sNSE and normal sLDH were of the mucosal type. NSE was detected in both supernatant and cell lysate of all four melanoma cell lines (0.30-237.32 ng/mL and 137-483.04 ng/mg, respectively). Two cell lines with a high supernatant NSE level contained many dead cells in the supernatant. The combination of sNSE and sLDH could contribute to the early detection of distant metastasis and disease condition evaluations for advanced melanoma patients.
Identifiants
pubmed: 32734632
doi: 10.1111/1346-8138.15502
doi:
Substances chimiques
Biomarkers, Tumor
0
Phosphopyruvate Hydratase
EC 4.2.1.11
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1141-1148Informations de copyright
© 2020 Japanese Dermatological Association.
Références
Homsi J, Kashani-Sabet M, Messina JL, Daud A. Cutaneous melanoma: prognostic factors. Cancer Control 2005; 12: 223-229.
Kluger HM, Hoyt K, Bacchiocchi A et al. Plasma markers for identifying patients with metastatic melanoma. Clin Cancer Res 2011; 17: 2417-2425.
Sullivan R. The challenge of developing useful blood-based biomarkers in melanoma. Br J Dermatol 2013; 168: 3-4.
Sirott M, Bajorin DF, Wong GY et al. Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer 1993; 72: 3091-3098.
Wan XB, Wei L, Li H et al. High pretreatment serum lactate dehydrogenase level correlates with disease relapse and predicts an inferior outcome in locally advanced nasopharyngeal carcinoma. Eur J Cancer 2013; 49: 2356-2364.
Wibe E, Paus E, Aamdal S. Neuron specific enolase (NSE) in serum of patients with malignant melanoma. Cancer Lett 1990; 52: 29-31.
Tofani A, Cioffi RP, Sciuto R et al. S-100 and NSE as serum markers in melanoma. Acta Oncol 1997; 36: 761-764.
Lorenz J, Dippold W. Neuron-specific enolase - a serum marker for malignant melanoma. J Natl Cancer Inst 1989; 81: 1754-1755.
Buzaid AC, Sandler AB, Hayden CL et al. Neuron-specific enolase as a tumor marker in metastatic melanoma. Am J Clin Oncol 1994; 17: 430-431.
Neuss H, Koplin G, Raue W, Chr R, Mall JW. Analysing the serum levels of tumor markers and primary tumor data in stage III melanoma patients in correlation the extent of lymph node metastases - a prospective study in 231 patients. Acta Chir Belg 2011; 111: 214-218.
Reintgen DS, Cox C, Slingluff CL Jr, Seigler HF. Recurrent malignant melanoma: the identification of prognostic factors to predict survival. Ann Plast surg 1992; 28: 45-49.
Ravishankar S, Nagarajan P, Curry JL et al. Giemsa is the optimal counterstain for immunohistochemical detection of BRAF V600E mutation status in pigmented melanomas. J Cutan Pathol 2016; 43: 722-724.
Rad HH, Yamashita T, Jin HY et al. Tyrosinase-related proteins suppress tyrosinase-mediated cell death of melanocytes and melanoma cells. Exp Cell Res 2004; 298: 317-328.
Angi M, Kalirai H, Prendergast S et al. In-depth proteomic profiling of the uveal melanoma secretome. Oncotarget 2016; 7: 49623-49635.
Isgró MA, Bottoni P, Scatena R. Neuron-specific enolase as a biomarker: Biochemical and clinical aspects. Adv Exp Med Biol 2015; 867: 125-143.
Haque A, Ray SK, Cox A, Banil NL. Neuron specific enolase: a promising therapeutic target in acute spinal cord injury. Metab Brain Dis 2016; 31: 487-495.
Wibe E, Hannisdal E, Paue E, Aamdal S. Neuron-specific enolase as a prognostic factor in metastatic malignant melanoma. Eur J Cancer 1992; 28: 1692-1695.
Amin MB, Edge S, Greene F et al. (eds.), AJCC Cancer Staging Manual, 8th edn. New York: Springer, 2017.
Fujisawa Y, Yoshikawa S, Minagawa A et al. Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma. Cancer Med 2019; 8: 2146-2156.
Namikawa K, Kiyohara Y, Takenouchi T et al. Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: an open-label, single-arm, multicenter phase II study. Eur J Cancer 2018; 105: 114-126.
Yamazaki N, Kiyohara Y, Uhara H et al. Long-term follow up of nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma. Cancer Sci 2019; 110: 1995-2003.